Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 5.7 to 3.9.
-
Busy address KBO
49 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
PHARMA MAR from Brussel, company number BE0634863713, closed financial year 2025 with a result of € 8,208 after tax. For that financial year PHARMA MAR recorded a gross margin of € 654,069 and equity of € 223,426. Compared with financial year 2024, the result moved from € 5,870 to € 8,208. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 20, 2026.
€ 223,426
▲ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 8,208
▲ 40% vs 2024
Profit after tax over the fiscal year.
€ 103,374
▼ 48% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 73,426.
People and assets in 2025
3.9
▼ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 532,895
▼ 12% vs 2024
€ 136,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,742
▼ 62% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 37,366
▲ 149% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 153,002
▼ 28% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 745,031 | € 780,079 | € 694,671 | € 654,069 | ▼ 6% |
| Profit after taxes | € 42,068 | € -789 | € 5,870 | € 8,208 | ▲ 40% |
| Equity | € 210,136 | € 209,347 | € 215,217 | € 223,426 | ▲ 4% |
| Total debts | € 782,776 | € 346,736 | € 311,704 | € 269,237 | ▼ 14% |
| Cash | € 238,760 | € 208,648 | € 196,992 | € 103,374 | ▼ 48% |
| Retained profit | € 60,136 | € 59,347 | € 65,217 | € 73,426 | ▲ 13% |
| Balance sheet total | € 992,913 | € 556,083 | € 526,921 | € 492,662 | ▼ 7% |
| Employees (FTE) | 6 | 5.7 | 4.3 | 3.9 | ▼ 0.4 |
Key figures of PHARMA MAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA MAR?
What happened at PHARMA MAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 8,208 (▲ 40% vs 2024). Source: NBB ↗
- Luis Mora Capitan became a director. NBB
- Elena Calleja Crespo became a director. NBB
- New establishment in Machelen (Brab.). KBO
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 42,068 profit in 2022 to € 8,208 profit in 2025.
Paid € 44,681 in corporate taxes since 2022.
Best year ever: 2022, with € 42,068 profit.
On average € 167,700 of value added per employee in 2025.
A new publication or filing at PHARMA MAR? We notify you, reason included.
Follow PHARMA MARDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMA MAR are Luis Mora Capitan and Elena Calleja Crespo. The shares are held by Pharma Mar S.A. (100%).
Directors
According to the 2025 annual accounts
Luis Mora Capitan
Director
since 2023
Elena Calleja Crespo
Director
since 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Drukpersstraat 4
1000 Brussel
Leonardo da Vincilaan 19
1831 Machelen (Brab.)
Active since 16 November 2015
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 49 companies are registered at this address.
All companies at this address →Grada
Société de Gestion patrimoniale et financière
€ 502,480 gross margin · 2025
Schalbroek
€ -20,347 gross margin · 2025
Immobilière du Boulevard
€ 31,024 gross margin · 2025
Société anonyme belge de la Forêt du Paular
€ -93,395 gross margin · 2025
+44 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0634.863.713
- VAT number
- BE 0634.863.713
- Registered office
- Drukpersstraat 4, 1000 Brussel
- Names & denominations
- PHARMA MAR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 August 2015
- Peppol
- Active · Active since 27 Mar 2025
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van overige farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Activiteiten van reclamebureaus